Return to content in this issue

 

Successful Desensitization to Daratumumab after Severe Life-Threatening Reaction in A Patient with Refractory Multiple Myeloma

Carrón-Herrero A1*, Solano-Solares E1*, Rita CG2**, Rodríguez-Martín E2**, Ruedas A4, Barbolla I4, Berges-Gimeno MP1,3***

1Allergology Department, Hospital Universitario Ramón y Cajal, IRYCS, Madrid
2Immunology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid
3Spanish Thematic Network and Co-operative Research Centres, ARADyAL, Spain
4Internal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid

*Both authors have equally contributed and should be both considered as first authors
**Both authors contributed to the in vitro studies and discussion
***Author should be considered as senior author

J Investig Allergol Clin Immunol 2021; Vol. 31(6)
doi: 10.18176/jiaci.0678

Key words: Daratumumab, Anaphylaxis, Desensitization, Multiple myeloma, Monoclonal antibody